These discoveries have assisted in establishing the clinical implications of ANP and BNP as biomarkers that detect cardiac disease including heart failure and cardiac hypertrophy, and ANP and BNP themselves and molecules relevant to them have been implicated in the development of therapeutic agents for heart failure or related diseases [29,30]. The gene discussed is NPPA; the disease is cardiac hypertrophy.